Cargando…

Comment on “Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU-Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?”

Detalles Bibliográficos
Autores principales:	Webster, Christopher J., Woollett, Gillian R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790339/ https://www.ncbi.nlm.nih.gov/pubmed/31372960 http://dx.doi.org/10.1007/s40259-019-00372-3

Ejemplares similares

A ‘Global Reference’ Comparator for Biosimilar Development
por: Webster, Christopher J., et al.
Publicado: (2017)

Comment on “The End of Phase 3 Clinical Trials in Biosimilars Development?”
por: Webster, Christopher J., et al.
Publicado: (2018)

PF-06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta(®)): Pharmacodynamics, Pharmacokinetics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers
por: Moosavi, Shahrzad, et al.
Publicado: (2020)

Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of teriparatide biosimilar with EU- and US-approved teriparatide reference products in healthy men and postmenopausal women
por: Fenwick, Steven, et al.
Publicado: (2022)

PF-06881893 (Nivestym™), a Filgrastim Biosimilar, Versus US-Licensed Filgrastim Reference Product (US-Neupogen(®)): Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers
por: Yao, Hsuan-Ming, et al.
Publicado: (2019)

An Efficient Development Paradigm for Biosimilars
por: Webster, Christopher J., et al.
Publicado: (2019)

A large multicentre, randomized, double‐blind, cross‐over study in healthy volunteers to compare pharmacokinetics, pharmacodynamics and safety of a pegfilgrastim biosimilar with its US‐ and EU‐reference biologics
por: Bellon, Anne, et al.
Publicado: (2020)

Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers
por: Choi, Chungam, et al.
Publicado: (2018)

Similar pharmacokinetics and pharmacodynamics of a new biosimilar and reference insulin aspart in healthy Chinese males
por: Liu, Hui, et al.
Publicado: (2021)

Worldwide experience with biosimilar development
por: McCamish, Mark, et al.
Publicado: (2011)

Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes
por: Cohen, Hillel P., et al.
Publicado: (2018)

Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin‐R with the US‐licensed Humulin® R formulation in healthy subjects: Results from the RHINE‐1 (Recombinant Human INsulin Equivalence‐1) study
por: Plum‐Mörschel, Leona, et al.
Publicado: (2022)

Author Correction: Similar pharmacokinetics and pharmacodynamics of a new biosimilar and reference insulin aspart in healthy Chinese males
por: Liu, Hui, et al.
Publicado: (2021)

PB2051: POPULATION PHARMACOKINETIC/PHARMACODYNAMIC/EFFICACY MODELING OF SB12 (PROPOSED ECULIZUMAB BIOSIMILAR) AND REFERENCE ECULIZUMAB
por: Lee, Hyuna, et al.
Publicado: (2023)

Clinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myelosuppressive chemotherapy
por: Desai, Kalpna, et al.
Publicado: (2018)

Comparability of Biosimilar Filgrastim with Originator Filgrastim: Protein Characterization, Pharmacodynamics, and Pharmacokinetics
por: Sörgel, Fritz, et al.
Publicado: (2015)

A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
por: Hummel, Matthew, et al.
Publicado: (2021)

Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US‐licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE‐3 (Recombinant Human INsulin Equivalence‐3) study
por: Plum‐Mörschel, Leona, et al.
Publicado: (2022)

Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg(®), a pegfilgrastim biosimilar in healthy subjects
por: Roth, Karsten, et al.
Publicado: (2019)

Authors’ Reply to Pires et al.: “Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes”
por: Cohen, Hillel P., et al.
Publicado: (2018)

Using Network Biology to Bridge Pharmacokinetics and Pharmacodynamics in Oncology
por: Kirouac, D C, et al.
Publicado: (2013)

Clinical Evaluation of Humira(®) Biosimilar ONS-3010 in Healthy Volunteers: Focus on Pharmacokinetics and Pharmacodynamics
por: Dillingh, Marlous R., et al.
Publicado: (2016)

The first biosimilar approved for the treatment of osteoporosis: results of a comparative pharmacokinetic/pharmacodynamic study
por: Takács, I., et al.
Publicado: (2018)

Meta‐analysis of Pharmacokinetic/Pharmacodynamic Results of 3 Phase 1 Studies with Biosimilar Pegfilgrastim
por: Gattu, Sreekanth, et al.
Publicado: (2021)

A randomized, double‐blind, comparative study of the pharmacodynamics and pharmacokinetics of GP40141 (romiplostim biosimilar) and reference romiplostim in healthy male volunteers
por: Makarenko, Igor, et al.
Publicado: (2023)

Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models
por: Zhang, Longfei, et al.
Publicado: (2022)

Confirmation of Biosimilarity in a Pharmacokinetic/Pharmacodynamic Study in Healthy Volunteers for an Analytically Highly Similar Pegfilgrastim
por: Desai, Kalpna, et al.
Publicado: (2016)

Pharmacokinetic and pharmacodynamic bioequivalence of proposed biosimilar MYL‐1501D with US and European insulin glargine formulations in patients with type 1 diabetes mellitus
por: Heise, Tim, et al.
Publicado: (2019)

HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects
por: Yang, Jingjing, et al.
Publicado: (2022)

Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of CMAB807, a New Denosumab Biosimilar, in Healthy Chinese Subjects
por: Chen, Hanjing, et al.
Publicado: (2022)

Future Evolution of Biosimilar Development by Application of Current Science and Available Evidence: The Developer’s Perspective
por: Cohen, Hillel P., et al.
Publicado: (2023)

Evolution of the EU Biosimilar Framework: Past and Future
por: Wolff-Holz, Elena, et al.
Publicado: (2019)

Pharmacokinetic and pharmacodynamic similarity evaluation between an insulin glargine biosimilar product and Lantus(®) in healthy subjects: Pharmacokinetic parameters of both parent insulin glargine and M1 were used as endpoints
por: Wang, Yiya, et al.
Publicado: (2022)

Clinical Pharmacology of Insulin Aspart Biosimilar GP40071: Pharmacokinetic/Pharmacodynamic Comparability in Hyperinsulinemic Euglycemic Clamp Procedure
por: Drai, Roman V., et al.
Publicado: (2022)

The Role of PD Biomarkers in Biosimilar Development – To Get the Right Answer One Must First Ask the Right Question
por: Woollett, Gillian R., et al.
Publicado: (2022)

Pharmacodynamic Biomarkers Evidentiary Considerations for Biosimilar Development and Approval
por: Strauss, David G., et al.
Publicado: (2022)

Comment on: “Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes”
por: Pires, Antonio, et al.
Publicado: (2018)

Pooled analysis of three pharmacokinetic studies comparing biosimilar MB02 and reference bevacizumab
por: Miguel‐Lillo, B., et al.
Publicado: (2023)

The Continuum of Comparability Extends to Biosimilarity: How Much Is Enough and What Clinical Data Are Necessary?
por: McCamish, M, et al.
Publicado: (2013)

Pharmacokinetic and pharmacodynamic bioequivalence of biosimilar MYL‐1601D with US and European insulin aspart in healthy volunteers: A randomized, double‐blind, crossover, euglycaemic glucose clamp study
por: Hövelmann, Ulrike, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_03h5mtmkhf9554dfjo663hbvo3